Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07529925) titled 'A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis' on April 8.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Condition: Severe Plaque Psoriasis in Chinese Children

Intervention: Drug: Adalimumab Solution for Injection

Recruitment Status: Not recruiting

Phase: Phase 4

Date of First Enrollment: May 2026

Target Sample Size: 30

To know more, visit https://clinicaltrials.gov/study/NCT07529925...